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ABSTRACT - Purpose Achieving successful gene therapy requires delivery of a gene vector specifically to the
targeted tissue with efficient expression and a good safety profile. The objective of this work was to develop,
characterize and determine if a novel gemini surfactant-based lipoplex systems, modified with a cancer-targeting
peptide p18-4, could serve this role. Methods The targeting peptide p18-4 was either chemically coupled to a
gemini surfactant backbone or physically co-formulated with the lipoplexes. The influence of targeting ligand and
formulation strategies on essential physicochemical properties of the lipoplexes was evaluated by dynamic light
scattering and small angle X-ray scattering techniques. In vitro transfection activity and cellular toxicity of
lipoplexes were assessed in a model human melanoma cell line. Results All lipoplexes zeta potential and particle
size were optimal for cellular uptake and physical stability of the system. The lipoplexes adopted an invertedhexagonal lipid arrangement. The lipoplexes modified with the peptide showed no significant changes in
physicochemical properties or lipoplex assembly. The modification of the lipoplexes with the targeting peptide
significantly enhanced protein expression 2-6 fold compared to non-modified lipoplexes. In addition, p18-4
modified lipoplexes significantly improved the safety of the lipoplexes. The ability of the p18-4 modified
lipoplexes to selectively express the model protein was confirmed by using healthy human epidermal
keratinocytes (HEKa). Conclusion The gemini surfactant-based lipoplexes modified with p18-4 peptide showed
significantly higher efficiency and safety compared to the system that did not contain a cancer targeting peptide
and provided evidence for their potential application to achieve targeted melanoma gene therapy.
__________________________________________________________________________________________
INTRODUCTION
In gene therapy, the efficiency of non-viral vectors
depends on the successful delivery and expression of
the exogenous genetic material into the targeted
tissue, while causing minimum toxicity. For cancer
gene therapy, non-viral gene delivery systems, which
usually assemble as nano-sized particles, have the
ability to non-specifically target the tumor (passive
targeting) by an enhanced permeability and retention
(EPR) effect, extravasation through the leaky
vasculature surrounding the tumors and entrapment
in the tumor mass.(1) However, passive cancer
targeting can be challenged by several factors
including, but not limited to, the type of cancer, the
heterogeneity of the tumor, blood supply, the
interaction of the nanoparticles with the tumor and
surrounding tissue, and the

characteristics of the delivery system.(2, 3). On the
other hand, cancer-specific targeting can be achieved
by decorating the non-viral delivery system with
cancer-specific ligands (active targeting). Such
ligands can be a small-molecule moiety, protein,
peptide or antibody (monoclonal antibody or
fragment) that can specifically bind to an
overexpressed enzyme, a receptor or a cancerspecific antigen.(4) Such targeting can enhance the
accumulation and

______________________________________
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interaction of the ligand-modified nanoparticles
which can improve their specific cellular
internalization. As a result of specific uptake by
cancer cells, off-target gene expression and toxicity
can be avoided or at least minimized.(5).
In cancer gene and drug delivery, different
ligands have been explored for cancer specific
targeting. These ligands include monoclonal
antibodies such as trastuzumab to target HER2
receptor in breast cancer, peptides such as arginylglycyl-aspartic acid (RGD) to target overexpressed
integrins, and small molecules such as folic acid to
target the folate-binding protein.(3) Among different
peptide ligands that have been explored for cancer
targeting is p160, a linear dodecapeptide
(VPWMEPAYQRFL) that was identified by phage
display. It displayed a superior affinity for
neuroblastoma cells and selective internalization in
different breast cancer cell lines but not by normal
umbilical
vein/vascular
endothelium
cells
(HUVEC).(6, 7) Based on the structure of p160,
several linear decapeptides have been engineered
with higher affinity to cancer cells (MDA-MB-435,
and MCF-7) and better enzymatic stability.(8)
Among
these
targeting
peptides,
p18-4
(WxEAAYQrFL) [Figure 1] demonstrated the
highest affinity and selectivity toward breast cancer
cells and showed resistance to proteolytic
degradation.(8)
Decoration
of
liposomaldoxorubicin with p18-4, as a cancer targeted drug
delivery system, significantly improved the cellular
uptake and cytotoxicity of doxorubicin selectivity in
breast cancer.(9) In mice bearing MDA-MB-435
tumour, the anti-cancer activity of the p18-4
modified liposomal-doxorubicin was improved in
comparison to the unmodified liposomal
system.(10).
Cationic gemini surfactants are cationic lipids
that have been comprehensively evaluated and
characterized for gene delivery.(11, 12) The
versatility in the chemical structure of gemini
surfactants makes it easy to produce highly efficient
gene delivery systems with a good safety profile.(1315) For example, chemical modification in the basic
structure of gemini surfactant by introducing amino
acid substituents in the spacer region, producing 127N(GK)-12 [Figure 1], has led to the production of
an efficient biocompatible carrier. The applicability
of topical gene delivery by cationic gemini
surfactants was evaluated previously for dermal,

vaginal and ocular applications.(13, 15, 16) The
positive outcome provided evidence for the viability
of using gemini surfactant-based lipoplexes for
topical and transdermal gene delivery. Recently, we
have reported the development and evaluation of an
RGD-modified gemini surfactant lipoplex system
that shows specificity to melanoma.(17) The
introduction of the RGD moiety into the gemini
surfactant structure enhanced the transfection
activity by more than two fold compared to nonmodified lipoplexes.(17) The successful targeting of
overexpressed integrin in a melanoma model
provided evidence for the potential of using gemini
surfactant-based lipoplexes for targeted cancer gene
therapy.
The objective of this work was to develop and
characterize a novel cationic gemini surfactant-based
lipoplex decorated with a specific cancer-targeting
ligand (p18-4) and to evaluate its activity in a
melanoma model. As well, we investigated the
influence of the ligand modification on the essential
physicochemical properties of the lipoplex system
that govern the transfection activity. The specificity
of the developed ligand-modified lipoplexes to target
melanoma cells was also examined.
MATERIALS & METHODS
Materials
N, N-diisopropylethylamine (DIPEA), 1-[bis
(dimethylamino) methylene] -1H-1,2,3-triazolo[4,5b]pyridinium 3-oxidehexafluorophosphate (HATU),
trifluoroacetic acid (TFA) and dimethyl sulfoxide
(DMSO spectroscopy grade) were purchased from
Sigma-Aldrich (Oakville, ON, Canada). Helper lipid
1 , 2 dioleyl – sn – glycerol phosphatidylethanolamine (DOPE) was purchased
from Avanti Polar Lipids, (Alabaster, AL, USA). 3(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) was purchased from Invitrogen
Corporation (Grand Island, NY, USA). All solvents
used were HPLC grade.
Synthesis of gemini surfactant and peptide p18-4
Synthesis and characterization of 12-7N(GK)-12
gemini surfactant was reported previously.(18)
Synthesis and characterization of linear peptide p184 were described previously.(9)
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Figure 1. Chemical structure of a) 12-7N(GK)-12, b) p18-4 peptide [p18-4] (WxEAAYQrFL) and c) 12-7N(p18-4)-12
gemini surfactant [p18-4-G]
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Synthesis of p18-4 modified gemini surfactant
Peptide p18-4 on the chlorotrityl resin (with all side
chain groups protected with Boc) was provided by
Dr. Kaur’s group. (8) The synthesis of gemini
surfactant backbone [3-(bis 3-(N-dodecyl-N,Ndimethylamino)propyl)carbamoyl propanoic acid]2+
2Cl- was described previously.(19) In brief, under a
N2 atmosphere using standard Schlenk techniques, a
Schlenk flask equipped with a magnetic stir bar was
charged with 3,3′ - iminobis ( N , N dimethylpropylamine) (1.682 g, 8.989 mmol) and
succinic anhydride (0.988 g, 9.873 mmol) in 15 mL
of DMF to form a homogeneous solution. After 3
days of stirring at ambient temperature, the reaction
mixture was concentrated under vacuum to obtain an
orange–yellow oily substance as the desired
compound in quantitative yield. The compound was
charged in a round-bottom flask with propanoic acid,
(800.0 mg, 2.785 mmol) and 1-iodododecane (2.063
g, 1.720 mL, 6.933 mmol) in DMF (20 mL) to form
a yellow homogeneous solution. After 12 h of
stirring at ambient temperature, the solvent was
removed under vacuum and the residue washed
several times with diethyl ether to remove the excess
iodododecane. The sample was dried, yielding an
orange oily substance that was dissolved in 10 mL of
distilled water and 2.5 equivalents of Amberlite®
IRA-400(Cl) (2.400 g, 6.933 mmol) was added to the
solution. After stirring for 1 h, the Amberlite resin
was removed by filtration and the residue washed
with water. An orange, oily substance [ 3 - ( bis 3 - (
N
–
dodecyl
–
N
,
N
dimethylamino)propyl)carbamoyl propanoic acid]2+
2Cl- was obtained in almost quantitative yield after
removing excess water by freeze-drying.
The gemini backbone was activated under a N2
atmosphere in a round bottom flask, by reacting [ 3 ( bis 3 - ( N – dodecyl – N , N dimethylamino )
propyl) carbamoyl propanoic acid]2+ 2Cl- (M.W.
696.96 g/mol) with (O-(7-azabenzotriazol-1-yl)-N
,N,N′,N′-tetramethyluronium hexafluorophosphate,
HATU) (1.2 eq, M.W. 380.23 g/mol) and (N,Ndiisopropylethylamine, DIPEA) (2 eq, M.W. 129.25
g/mol) in 10 mL of dry DMF at room temperature for
15 min.
For the coupling reaction, a solid phase peptide
synthesis vessel [Medium Frit, GL 25 thread, Fritted
Disc. Dia./25] (Chemglass Life Sciences, Vineland,
NJ, USA) was charged with [p18-4]-chlorotrityl
resin and activated gemini surfactant (1:5 moles) in
10 mL of dry DMF. The coupling reaction was
carried out for 3 days with continuous shaking and

the solution removed from the vessel. The peptidegemini surfactant was cleaved from the resin and all
protecting groups were removed by using 50:50
TFA/DCM, 5% TIPS at room temperature for 1 h (3
times). The solution containing the modified gemini
surfactant [p18-4-G] was collected and concentrated
by rotary evaporation. The product was dissolved in
50:50 (v/v) H2O/methanol and subjected to 3 cycles
of cold acetone precipitation. The structure of the
compound was confirmed by using an API QSTAR
XL MS/MS hybrid QqToF tandem mass
spectrometer equipped with an ESI source (Applied
Biosystems Inc., CA, USA). ESI m/z 634 [M+H]3+
(expected m/z for [M+H]3+ is 634.758).
Lipoplex formulations
The construction of the plasmid pGThCMV.IFNGFP, used as a model for a robust plasmid, was
described previously.(13) Plasmid DNA (coded as P
in lipoplexes) was isolated and purified using
QIAGEN Plasmid Giga Kit (Mississauga, ON,
Canada) following the manufacturer’s protocol.
Aqueous
solutions
of
3
mM
gemini
surfactant/peptide were used to prepare all lipoplex
formulations evaluated in this work.
Lipoplexes, Table 1, were formulated using a
plasmid to gemini surfactant (phosphate/nitrogen)
charge ratio of 1:10 in the presence of (DOPE) as a
helper-lipid (coded as L in lipoplexes) creating
plasmid/gemini surfactant/lipid lipoplexes [P.G.L],
as described previously.(17) In brief, The DOPE
were vesicles formed by sonication in 9.25% sucrose
solution (pH 9) at a final concentration of 1 mM
DOPE and filtered through Acrodisc® 0.45 µm
syringe filters (Pall Gelman, Ann Arbor, MI). The
[P/G] lipoplexes were prepared by mixing an aliquot
of 200 µg pDNA aqueous solution with an
appropriate amount of 3 mM gemini surfactant
solution and incubated at room temperature for 20
min. The [P.G.L] systems were prepared by mixing
[P/G] lipoplexes with the DOPE vesicles at gemini
surfactant to DOPE molar ratio of 1:10 and incubated
at room temperature for 20 min.
Peptide-modified lipoplex formulations were
prepared in two different ways (as described
earlier)(17). Briefly,10% of total non-modified
gemini surfactant, 12-7N(GK)-12, was substituted
by either peptide-modified gemini surfactant (p18-4G) in L2 and L3, (Table 1) or targeting peptide (p184) in L4 and L5 (Table 1).
Size and zeta potential measurements
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Formulations (800 µL of each) were transferred into
a special cuvette (DTS1061, Malvern Instruments,
Worcestershire, UK) for size distribution and zetapotential measurements using a Zetasizer Nano ZS
instrument (Malvern Instruments, Worcestershire,
UK). Each sample was measured four times, and the
results are expressed as an average ± standard
deviation (SD) of a triplicate with corresponding
polydispersity index (PDI) value (Table 2).

was used to plot diffraction intensity versus 2θ
(where θ is the diffraction angle) or q (scattering
vector) by radial integration of the 2D patterns.
Cell culture and in vitro transfection
Human malignant melanoma (A375) cell line
(ATCC® CRL-1619™) was cultured in Dulbecco's
modified Eagle's medium (DMEM) supplemented
with 10% fetal bovine serum and 1% antibiotic and
incubated at 37 °C under an atmosphere of 5%
CO2/95% air. Normal adult human epidermal
keratinocyte cells (HEKa,C-005-5C, Cascade
Biologics, Invitrogen), were grown on a T-75 Cell+
tissue culture flask (Sarstedt AG & Co.) in Medium
154
(Gibco)
supplemented
with
Human
Keratinocyte Growth Supplement (HKGS, Gibco),
10% fetal bovine serum and 1% antibiotic and
incubated at 37 ˚C under an atmosphere of 5%
CO2/95% air.
The day prior to transfection, cells were seeded
in 96-well tissue culture plates (BD Mississauga,
ON, Canada) at a density of 1.5×104 cells/well for
A375 and HEKa cell line at a density of 2×104

Small-angle X-ray Scattering (SAXS) analysis
Small-angle X-ray Scattering (SAXS) measurements
were carried out at the Stanford Synchrotron
Radiation Lightsource, Menlo Park, CA, California.
Lipoplexes prepared as described above were
concentrated (10x) by speed vacuuming at 35 ˚C. A
wavelength of 1.1271 Å (11KeV energy) was
utilized. Samples were loaded in 1.5mm boron-rich
glass capillaries (Charles Supper Company, USA).
The scattered X-ray was detected on MAR225-HE
(225 mm x 225 mm (3072 x 3072 pixels, pixel size
73.24 μm) at 20 s exposure time and at a sample to
detector distance of 1.1 m. The SAXS detector was
calibrated with silver behenate. GSASII software

Table 1. Preparation methods used for formulations evaluated. All lipoplex systems prepared at 1:10 -/+ charge ratio and
with helper lipid DOPE. P: pDNA, G:12-7N(GK)-12, L: DOPE, p18-4-G : 12-7N( p18-4)-12, p18-4: p18-4 linear
peptide.
ID

Preparation of Peptide modified lipoplex

Peptide/Peptide-gemini surfactant

System produced

L1

Conventional

--

[P.G.L]

L2

Chemical conjugation

10% 12-7N(p18-4)-12

Ch[P.G.p18-4-G.L]

L3

Chemical conjugation

10% 12-7N(p18-4)-12

Ch[P.G.L].p18-4-G

L4

Physical co-administration

10% p18-4

Ph[P.G.p18-4.L]

L5

Physical co-administration

10% p18-4

Ph[P.G.L].p18-4

L6

Chemical conjugation

100% 12-7N(p18-4)-12

Ch[P.G.p18-4-G.L]

Table 2 Physiochemical properties (size and zeta potential) of different p18-4 modified lipoplexes formulations. Size and zeta
potential measurements: values are an average of n = 3 ± standard deviation (SD). The polydispersity (PDI) index is indicated
for the size measurements as an average of three measurements ± STD.
Particle size
Preparation Method
System produced
PDI ± SD
ζ-potential (mV) ± SD
(nm) ± SD
Conventional

L1: [P.G.L]

157 ± (2.5)

0.251 ± (0.003)

22 ± (1.03)

Chemical conjugation

L2: Ch[P.G.p18-4-G.L]

Chemical conjugation

L3: Ch[P.G.L].p18-4-G

144 ± (0.5)
145 ± (2.4)

0.296 ± (0.019)
0.268 ± (0.002)

19.5 ± (0.68)
17.7 ± (1.45)

Physical co-administration

L4: Ph[P.G.p18-4.L]

163 ± (2)

0.295 ± (0.014)

17 ± (2.32)

Physical co-administration

L5: Ph[P.G.L].p18-4

174 ± (2.8)

0.364 ± (0.014)

15.2 ± (1.76)
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cells/well in 96-well Cell+ tissue culture plate
(Sarstedt AG & Co.). One hour before treatment, the
media was replaced with non-supplemented media.
Four wells per formulation were transfected with
lipoplexes containing 0.2 µg pGThCMV.IFN-GFP
plasmid/well.
Lipofectamine
Plus
reagent
(Invitrogen Life Technologies) was used according
to the manufacturer’s protocol as a positive control
with 0.2 µg pDNA/well. The 96-well tissue culture
plates were then incubated at 37 °C under 5% CO2
and 95% air. After 5 h, the media was removed and
replaced with fresh supplemented media.
Supernatants containing the secreted IFN-γ were
collected at 24 and 48 h and replaced with fresh
supplemented media. The collected supernatants
were stored at -80 ˚C until further evaluated.

the average of three independent experiments ± SD.
One way analysis of variance (ANOVA, Dunnett's
test) was used for statistical analyses. Significant
differences were considered at p < 0.05 level.
RESULTS
The influence of p18-4-modification on the
physicochemical characteristics of the lipoplexes
Physicochemical properties that control the
transfection activity and stability of lipoplexes are:
particle size, surface charge and lipid assembly.(21,
22) All lipoplexes formed particles with an average
diameter of less than 180 nm. The average particle
size of the non-modified lipoplexes (L1: [P.G.L])
was 157±2.5 nm (Table 2). Substitution of 10% of
the parent gemini surfactant [12-7N(GK)-12] with
the p18-4 conjugated gemini surfactant (p18-4-G)
(L2: Ch[P.G.p18-4-G.L] and L3: Ch[P.G.L].p184-G), caused a decrease in particle size to 144±0.5
nm and 145±2.4, respectively. On the other hand,
physical co-formulation of free p18-4 peptide with
the lipoplex system caused an increase in the average
size of the assembled nanoparticles with wide poly
dispersity index values. For example, the addition of
10% free p18-4 to the formed lipoplexes [P.L.G]
(L5: Ph[P.G.L].p18-4) caused an increase of 17 nm
compared to non-modified lipoplexes (L1: [P.G.L]).
Zeta potential measurements indicated that all
lipoplexes carry an overall positive charge in the
range of 22-15 mV. The substitution of 10% of nonmodified gemini surfactant (12-7N(GK)-12) with
p18-4 gemini surfactant or free p18-4 peptide caused
a decrease in zeta potential values. For example,
L5:Ph[P.G.L].p18-4 showed the most significant
reduction in zeta potential value of over 30%
compared to the non-modified formulations
(L1).(Table 2).
The influence of the addition of the targeting
peptide on the lipid phase arrangement and
transitions of the lipoplexes was examined using
SAXS [Figure 2]. All lipoplexes exhibited Bragg’s
peaks with relative ratios of 1, √3 and √4,
characteristic of an inverted hexagonal phase
arrangement (HII). The preparation method and
presence or absence of targeting peptide-modified
gemini surfactant or free targeting peptide in the
lipoplex system did not cause any alteration in the
lipid phase arrangement.

Transfection activity (ELISA)
Enzyme-linked immunosorbent assay (ELISA) was
performed using Immulon 2 flat bottom 96-well
plates (Greiner Labortechnik, Frickenhausen,
Germany) following the BD Pharmingen protocol as
previously described.(20) The concentration of
expressed IFN-γ was calculated from a standard IFNγ curve using recombinant mouse IFN-γ standard
(BD Pharmingen, BD Biosciences).
Cytotoxicity assay
MTT assay was used to evaluate the cellular toxicity
of lipoplex systems in A375 and HEKa cell lines. A
sterile solution of 4 mg/mL of MTT in PBS buffer
was prepared. Cell lines were seeded on 96-well
plates and transfected with lipoplexes (as described
above). After 48 h, the cell lines were evaluated for
cytotoxicity. The supplemented media was removed
from the wells and replaced with 0.5 mg/mL MTT in
supplemented media and incubated at 37 C in 5%
CO2 and 95% air for 3 h. The supernatant was
removed and each well washed with PBS. The purple
formazan crystal that formed was dissolved in
DMSO. Plates were incubated for 10 min at 37 C.
Absorbance was measured at 580 nm using BioTek
microplate reader (Bio-Tek Instruments, VT, USA).
The cellular toxicity is expressed as a percentage of
the non-transfected control cells ± SD.
STATISTICAL ANALYSIS
Statistical analyses were performed using SPSS
software (Version 23.0). The results are expressed as
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Figure 2. SAXS profile of [P.G.L] lipoplexes constructed at 1:10 -/+ charge ratio and with helper lipid DOPE (L) in all
formulation. P: pDNA, G:12-7N(GK)-12, L: DOPE, p18-4-G : 12-7N( p18-4)-12, p18-4: p18-4 linear peptide.

In vitro evaluation
Transfection efficiency and cellular toxicity
To determine the optimum formulation strategy and
amount of targeting peptide leading to the highest
gene expression and lowest cellular toxicity, the
transfection efficiency of the p18-4-modified
lipoplexes was evaluated in human malignant
melanoma (A375) cell line. Different concentrations
of p18-4 modified gemini surfactant or free p18-4 (5,
10, 15, 20% and 100% of the total amount of cationic
lipid) were tested. The highest levels of gene
expression (IFN-γ level by ELISA) were observed
when 10% of p18-4 conjugated gemini surfactant
(p18-4-G) or physical co-formulation of free p18-4
was used [Figure 3 A]. ]. Lipoplexes formulated with

100% of p18-4 conjugated gemini surfactant (p18-4G) showed a negligible level of gene expression
[data not shown]. Incorporation of p18-4 modified
gemini surfactant in the lipoplexes (either during the
formation of lipoplexes, L:2 Ch[P.G.p18-4-G.L] ,
or after the formation of [P.L.G] lipoplexes, L3:
Ch[P.G.L].p18-4-G) resulted in a 3-fold increase in
IFN-γ level compared to standard non-targeting
lipoplexes [P.G.L] [Figure 3 A]. The highest level of
gene expression was obtained when lipoplexes were
formulated by physical co-formulation of free p18-4
(L4: Ph[P.G.p18-4.L] and L5: Ph[P.G.L].p18-4)
with over a 6-fold increase being observed
(1252±402 and 1152±328 pg IFN-γ/1.5×104 A375
cells, respectively) [Figure 3 A].
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Figure 3 (A) IFN-γ expression in A375 cells at 48-h post-treatment with lipoplexes constructed at 1:10 -/+ charge ratio. P:
pDNA, G:12-7N(GK)-12, L: DOPE, p18-4-G : 12-7N( p18-4)-12, p18-4: p18-4 linear peptide. (Ch) indicates lipoplexes
chemically conjugated p18-4-G and (Ph) lipoplexes physically co-formulated with free p18-4. IFN-γ level determined by
ELISA. Significant increases (* p<0.01, one-way ANOVA) in IFN- expression were observed in all p18-4 modified
lipoplexes compared to non-modified lipoplexes (L1:[P.G.L]). (B) Cell viability in the same A375 cells after a 48-h treatment
with p18-4-modified lipoplex formulations as determined by MTT assay. Cell viability values are given as % relative to nontransfected cells. Four wells of each formulations were loaded on three different plates. The results are expressed as the mean
of the three plates (n = 3). Bars represent standard deviation. * Indicates significance at p < 0.05 in comparison to standard
formulation [P.G.L] (L1)
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The influence of targeting peptide on the cellular
toxicity of the lipoplexes was assessed by MTT assay
[Figure 3 B]. 48-h post-transfection, the cell viability
for non-modified lipoplexes L1:[P.G.L] was
approximately 30% of the non-transfected cells
[Figure 3 B]. Higher cell viability values were
reported for lipoplexes formed with 10% chemically
modified gemini surfactant (L2: Ch[P.G.p18-4G.L] and L3:Ch[P.G.L].p18-4-G). Physical coadministration of free p18-4 with also showed an
improvement in cellular viability compared to
standard lipoplexes. Both p18-4 modified gemini
surfactant (p18-4-G) and free targeting peptide (p184) caused no or minimal toxicity to A375 cell line
[Figure 3 B].

potential application as a non-invasive topical
transfection agent for development of vaginal
genetic vaccination.(15) In addition, by chemically
modifying the 12-7N(GK)-12 with cRGD, to target
over-expressed integrin receptor on melanoma, led
to a significant increase of gene expression.(17) The
ability of the RGD-modified lipoplexes to
specifically target overexpressed α3/β1 integrin in
melanoma was confirmed by using a positive
competitor peptide (free RGD) and false-negative
control peptide (RAD). As well, the RGD-modified
gemini surfactant lipoplex did not enhance the
transfection activity in normal human epidermal
keratinocytes (HEKa), indicating the selectivity of
the system toward the target.(17).
The nature of the nano-carriers, such as
modification of the chemical structure, and
formulation
strategies
can
influence
the
physicochemical properties of the lipoplex system,
ultimately affecting the transfection efficiency. The
size, shape and overall charge of the assembled
lipoplexes can influence the physicochemical
stability of the gene delivery system, its biodistribution, cellular uptake, gene expression, and
cellular toxicity.(27) Gemini surfactant-based
lipoplexes [P.L.G] can be internalized by
mammalian cells via clathrin-mediated or caveolaemediated endocytosis pathways.(28) Modification of
the chemical structure of the gemini surfactant
influenced the shape of the lipoplexes and hence the
main endocytosis uptake mechanism. For example,
lipoplexes build with 12-7NH-12 gemini surfactant
formed spherical-shape nanoparticles and were
internalized mainly through a clathrin-mediated
pathway. On the other hand, the modification of the
gemini surfactant with a dipeptide moiety in the
spacer region (i.e., 12-7N(GK)- 12) resulted in the
formation of cylindrically shaped lipoplexes with
larger particle size. This lipoplex system
demonstrated pH sensitive characteristics and
internalized the cells through caveolae-mediated
endocytosis.(28) In the current work, co-formulation
of lipoplex systems with free p18-4 (L4:
Ph[P.G.p18-4.L] and L5: Ph[P.G.L].p18-4)
showed the highest transfection efficiency with a 6fold increase in IFN-γ level compared to standard
lipoplexes L1: [P.G.L] [Figure 3 A]. The lipoplexes
assembled in larger nanoparticles (>150 nm) with a
polymodal particle distribution compared to the
standard lipoplexes (L1 [P.G.L]).

Targeting efficiency
The specificity of p18-4 modified lipoplexes to
target melanoma cell lines was examined by
transfecting primary human epidermal keratinocytes
(HEKa) with standard lipoplexes, p18-4-G modified
lipoplexes and lipoplexes co-formulated with free
p18-4 (L1: [P/G/L], L2: Ch[P.G.p18-4-G.L] and
L5: Ph[P.G.L].p18-4) [Figure 4 A]. The IFN-γ level
after 48 h of transfection with L2: Ch[P.G.p18-4G.L] was similar to the level achieved by standard
non-modified lipoplexes L1: [P/G/L]. Transfection
with L5: Ph[P.G.L].p18-4 showed a slight, but not
significant (p>0.05), increase in expressed IFN-γ
level compared to standard [P.G.L] lipoplexes.
MTT assay showed that targeting lipoplexes
marginally enhanced the cellular viability in HEKa
cell lines in comparison to standard [P.G.L]
lipoplexes [Figure 4 B].
DISCUSSION
Gene therapy for cancer is the most extensively
explored amongst worldwide gene therapy clinical
trials as 64.6% ( 1,590 trials) are investigating the
potential of cancer gene therapy.(23) Creating an
efficient and targeted gene delivery agent with
effective therapeutic outcomes and good safety
profile are required for successful clinical
applications. Targeting tumors with lipid-based gene
delivery systems can be achieved by chemically
modifying the lipoplexes with tumor specific
ligands.(24-26) Gemini surfactant-based lipoplexes
have been widely explored for gene delivery as they
show good transfection efficiency and low cellular
toxicity. The glycyl-lysine modified gemini
surfactant used in this work, 12-7N(GK)-12, showed
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Figure 4 (A) IFN-γ expression in HEKA cell line at 48-h post-treatment with lipoplexes constructed at 1:10 -/+ charge ratio
non-modified lipoplexes (L1:[P.G.L]), p18-4 chemically-conjugated lipoplexes (L2: Ch[P.G.p18-4-G.L]) and p18-4 peptide
co-formulated with the lipoplexes (L5: Ph[P.G.L].p18-4). IFN-γ level determined by ELISA. (B) Cell viability of HEKA
cells after a 48-h treatment with p18-4-modified lipoplex formulations as determined by MTT assay. Cell viability values are
given as % relative to non-transfected cells. HEKA cell line is normal adult human epidermal keratinocyte cells which express
normal level of integrins. No statistical significates was observed between non-modified lipoplexes and p18-4- modified
lipoplexes. Four wells of each formulations were loaded on three different plates. The results are expressed as the mean of
the three plates (n = 3). Bars represent standard deviation.
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The heterogeneity of the size of these lipoplexes
might have contributed to alterations in cellular
uptake mechanisms, leading to an improvement in
gene expression.(29) The modifications of the
lipoplexes with targeting p18-4 peptide did not
influence the supramolecular assembly, as all
lipoplexes evaluated in this work arranged into
inverted hexagonal structures (HII) [Figure 2]. This
lipid phase arrangement is believed to contribute to
the ability of the gemini based lipoplexes to interact
with the cell membrane and facilitate the endosomal
escape of the pDNA upon endocytosis.(13, 30)
The use of peptide penetration enhancers has
been widely explored to enhance the uptake of highly
hydrophobic drugs and in gene delivery. For skin
delivery, these peptides interact with skin proteins
(namely keratins which are highly expressed in the
skin) and enhance the transcellular uptake of drug
molecules.(31) In normal skin conditions, keratins (a
family of intermediate filaments) are the main
structural proteins in the epidermis (mainly type II
keratin KRT1 and KRT10 which mainly expressed
in keratinocytes) and they show important role in
maintaining skin integrity and in intracellular
signaling pathways.(32) Mutations in keratins
expressions are contributed to several skin hereditary
disorders.(32, 33) In addition, several keratins
showed distinctive expression (upregulated or
downregulated) in certain cancers (such as lung,
breast and skin cancers) and can be used for disease
diagnosis and monitoring.(32) The linear
dodecapeptide peptide p18-4 is able to bind
preferably to cancerous cells (MDA-MB-435 and
MCF-7) and internalized upon binding through
endocytosis.(9, 10) In a MDA-MB-435 xenograft
mouse model, p18-4 conjugated doxorubicin showed
a 5-fold reduction in tumor size compared to the free
drug.(9, 10) p18-4 specifically interacts with
overexpressed KRT-1 in MDA-MB-435 and MCF-7
cells.(34) In the current work, we evaluated the
ability of p18-4 modified lipoplexes to target
melanoma using a model cell line (A375) showing
overexpression of keratins.(35, 36) The increase in
gene expression by the p18-4 modified lipoplexes
could be attributed to the specific interaction of p184 with keratins and lead to improvement of cellular
uptake of the lipoplexes and higher transfection
activity [Figure 3 A]. We believe that the
combination of heterogeneity of particle size and the
availability of free p18-4 (not covalently bound to
gemini surfactant) on the surface of the lipoplexes to
interact with keratins in formulations L4 and L5 can

explain the significant increase in transfection
compared to non-modified (L1) and chemically
modified lipoplexes (L2 and L3). The results of the
control study (the transfection in HEKa cells which
express a normal level of keratins) indicate the
targeting specificity of the p18-4 modified lipoplexes
to melanoma [Figure 4 A].
CONCLUSIONS
The results of this study show that gemini surfactant
based lipoplexes modified with targeting peptide
(p18-4) are able to deliver pDNA to melanoma and
achieve higher gene expression with a good safety
profile. The specificity of melanoma targeting for the
lipoplexes was demonstrated by the higher gene
expression
compared
to
non-malignant
keratinocytes. The ability of the targeted lipoplexes
to interact specifically to overexpressed keratins in
melanoma and to enhance their penetration into the
tissue indicate the potential application of the system
for topical gene delivery.
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